According to recent reports, avasimibe can inhibit the progression of cholangiocarcinoma by targeting the FoxM1-AKR1C1 signalling pathway and induce apoptosis and cycle arrest to inhibit glioma tumour growth [32, 33]. This evidence concerns the gene FOXM1 and central nervous system cancer.